Evaluate the biodistribution of HyperMabs protein biologics therapeutics
HyperMabs is a biopharmaceutical company that designs and develops innovative therapeutics targeting lung diseases. HyperMabs is currently evaluating a drug candidate developed using in-silico methods to target lung disease. For this project, we aim to study the biodistribution of HyperMabs therapeutic, currently in its pre-clinical stage designed to treat several lung diseases. To achieve this, we wish to label the HyperMabs therapeutic with a labeling molecule to facilitate visualization of distribution of the therapeutic in lungs. The results obtained from this study will help the company to understand the efficacy of the drug which is crucial in optimising the dosing parameters to achieve maximum therapeutic benefits.